Nationwide Children's Hospital

Grant will lead to the creation of USDHub, a novel research tool bringing together research and clinical data from hundreds of thousands of kidney stone patients of all ages PHILADELPHIA, Oct. 15, 2024 /PRNewswire/ -- Researchers from Children's Hospital of Philadelphia (CHOP) and Vanderbilt University Medical Center were awarded a $7.37 million RC2 grant from the National Institutes of Health (NIH) to lead a five-year multisite project across the U.S. focused on kidney stone disease research. Continue Reading Dr. Gregory Tasian Led by CHOP pediatric urologist, Gregory Tasian, MD, MSc, MSCE and Vanderbilt University Medical Center urologist, Ryan Hsi, MD, the goal of this initiative is to establish a new research tool called the Urinary Stone Disease Hub (USDHub), which will aggregate data from across healthcare systems and research networks into one comprehensive platform drawing data from a cohort of more than 230,000 patients suffering from kidney stone disease. Urinary stone disease is a painful condition that can cause a substantial amount of suffering for affected patients. The prevalence of kidney stones is about 11% in Americans, and kidney stones send more than half a million patients to the emergency room each year, according to the National Kidney Foundation. Although urinary and kidney stones are traditionally thought of as an adult diagnosis, kidney stones in children are becoming more common, and CHOP clinicians encounter them daily. To address the unique needs of children with kidney stones, CHOP created the Pediatric Kidney Stone Center, a multidisciplinary program within its Divisions of Urology and Nephrology that is solely dedicated to the dietary, medical, and surgical management of kidney stones. There have been few advancements in the diagnosis and management of urinary stone disease, partly due to a lack of datasets that contain clinically important information about individuals with urinary stone disease across the lifespan. To help address these challenges, USDHub will draw from medical expertise across adult and pediatric urology and nephrology and combine informatics and AI to establish a novel data resource that includes clinically important information from CT images, clinical notes, stone composition, and 24-hour urine labs, which are not available in existing research databases. "We see this painful condition more frequently now, but strong evidence to support decisions about treating children is lacking because urinary stone disease was once rare," said Tasian, who holds the Cheers for CHOP Chair in Clinical Epidemiology of Pediatric Urological Disease. "Opportunities exist both for expanding the evidence base around the management of kidney and urinary stones and for improving the research process itself." In addition to the work being led by Drs. Tasian at CHOP and Hsi at Vanderbilt, USDHub will involve seven other sites involved are part of the STAR and PEDSnet, which are two PCORnet clinical research networks that have standardized electronic health record data. In addition to CHOP and Vanderbilt University Medical Center, USDHub sites include University of North Carolina, Medical University of South Carolina, Duke University, Texas Children's Hospital, Nationwide Children's Hospital, Lurie Children's Hospital of Chicago and Cincinnati Children's Hospital. "USDHub will be a collaborative effort to synergize efforts and expertise across adult and pediatric stone disease, and to engage patients and caregivers in the design process to ensure that our sustainable data access model meets their needs," Tasian said. "This program will finally provide us with longitudinal data and eliminate our reliance on single-center data sources that segregate pediatric and adult patients. We see the potential to significantly accelerate and improve urinary stone disease research." This research is funded by the National Institute of Diabetes and Digestive and Kidney Diseases (grant 1RC2DK140865-01). About Children's Hospital of Philadelphia: A non-profit, charitable organization, Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, the hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. The institution has a well-established history of providing advanced pediatric care close to home through its CHOP Care Network, which includes more than 50 primary care practices, specialty care and surgical centers, urgent care centers, and community hospital alliances throughout Pennsylvania and New Jersey, as well as the Middleman Family Pavilion and its dedicated pediatric emergency department in King of Prussia. In addition, its unique family-centered care and public service programs have brought Children's Hospital of Philadelphia recognition as a leading advocate for children and adolescents. For more information, visit . Contact: Kaila Revello Children's Hospital of Philadelphia (610) 457-5916 [email protected] SOURCE Children's Hospital of Philadelphia WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the following upcoming October 2024 investor conferences: Lytham Partners Fall 2024 Investor Conference Date and Time: Tuesday, October 1, 2024 at 4:15 p.m. ETLocation: Virtual Format: Fireside Chat and 1x1 MeetingsRegistration link for the event: https://lythampartners.com/fall2024invreg 3rd Annual ROTH Healthcare Opportunities Conference Date: Wednesday, October 9, 2024Location: New YorkFormat: 1x1 Meetings A replay of the fireside chat at the Lytham Partners Fall 2024 Investor Conference will be available shortly after the conference on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the meeting. About Fortress Biotech Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has seven marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital and Sentynl. For more information, visit www.fortressbiotech.com. Company Contact:Jaclyn JaffeFortress Biotech, Inc.(781) 652-4500ir@fortressbiotech.com Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com

Facilitating the Safe Integration of Bispecific Antibodies into Community Oncology NEW YORK, Sept. 25, 2024 /PRNewswire/ -- Canopy, the first Continuous Care Platform for oncology, today announced platform-wide support for bispecific antibodies. This support includes Remote Therapeutic Monitoring, smart triage algorithms, and decision-support pathways for CRS and ICANs. Bispecific antibodies (BsAbs) are a next-generation advancement in monoclonal antibody (mAb) therapy. By simultaneously targeting two antigens or epitopes, they can elicit multiple physiological or anti-tumor responses, acting like a "cocktail" of two mAbs. This dual-targeting approach produces significant treatment effects. With 10 BsAbs already approved across both solid tumors and hematologic cancers—including the recent approval in non-small cell lung cancer—and over 220 oncology-focused BsAbs currently in development, the adoption of these therapies in community oncology is expected to grow rapidly.1 However, BsAbs bring a combination of novel toxicities and complex management guidelines. These range from common symptoms, such as diarrhea or rash that may be severe and appear at unpredictable times, to dangerous conditions, including Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), or even rare and potentially life-threatening toxicities. As a result, oncology practices face multiple barriers to adoption, especially in the outpatient setting, including the need for specialized protocols and training and the integration of high-frequency remote patient monitoring into clinical operations. "Patients receiving these treatments require vigilant monitoring and nuanced management to ensure safety. Canopy's technology plays a crucial role in keeping patients safe when they're away from the clinic, especially when administering bispecific antibodies and CAR-T in the outpatient setting," said James Essell, MD, Medical Director of the Center for Cancer and Cellular Therapy at Oncology Hematology Care (OHC) and The Jewish Hospital, and Chair for Cellular Therapy at Sarah Cannon Research Institute. With Canopy, practices can seamlessly monitor their patients for BsAbs-induced toxicities, including CRS and ICANS. Smart monitoring schedules check in with patients through digital assessments via app, web, or phone. Canopy's intelligent triage algorithms allow busy nurses to focus on the patients who need them the most and enable rapid issue resolution with standardized symptom pathways. "The clinical impact of continuous care models, especially those incorporating ePRO-based monitoring, has been widely demonstrated in oncology, showing significant benefits for patients," said Michael Kolodziej, MD, Chief Medical Officer of Canopy. "As new therapies like bispecific antibodies become more common, these models are now essential for safely and effectively managing care in the outpatient setting." Studies of the Canopy ePRO and Platform demonstrate positive clinical outcomes for patients, including a 22% reduction in ER visits and hospitalizations and up to a 45% increase in treatment persistence at 3 months.2,3 "At Canopy, we've traditionally focused on supporting practices with managing existing patients on therapy. Now, we're incredibly proud to go beyond that by supporting practices in adopting new and life-saving therapies," said Lavi Kwiatkowsky, Founder & CEO of Canopy. Canopy recently announced partnerships with New York Cancer & Blood Specialists, Oncology Consultants, The Toledo Clinic Cancer Centers, and Northwest Hematology & Oncology, rapidly growing its network of leading oncology practices. For more information, visit . About Canopy: Canopy provides oncology practices with a comprehensive platform for all the care that happens between visits. Canopy's multi-channel ePRO and remote triage system enable practices to identify and prioritize patients who need help, resolve their issues using intelligent software, and generate new reimbursement streams from high-quality care. For more information, visit . Media Contact: Kaitlin Hemric [email protected] 704-838-6168 References: McKesson. (2023). Integrating bispecific antibody treatments into your community oncology practice: Internal McKesson analysis using ODIN 2.0 release September 2023. McKesson. Kolodziej, M. A., Kwiatkowsky, L., Parrinello, C., Thurow, T., Schaefer, E. S., Beck, J. T., Cherny, N., & Blau, S. (2022). ePRO-based digital symptom monitoring in a community oncology practice to reduce emergency room and inpatient utilization. Journal of Clinical Oncology, 40(16_suppl), 1508. Parrinello, C., Calkins, G., Kwiatkowsky, L., Schaefer, E. S., Beck, J. T., Ellis, A. R., Blau, S., Telivala, B. P., & Kolodziej, M. A. (2022). Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting. Journal of Clinical Oncology, 40(16_suppl), 1528. DOI: 10.1200/JCO.2022.40.16_suppl.1528 SOURCE Canopy WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED